Details of the Drug Reposition

General Information of This Drug (ID: DMBLID9)

Drug Name
N-acetylcysteine   DMBLID9
Synonyms
N-Acetyl-L-cysteine; acetylcysteine; 616-91-1; N-Acetylcysteine; mercapturic acid; Acetadote; L-Acetylcysteine; Broncholysin; Fluimucil; Mucomyst; N-Acetyl-cysteine; Parvolex; Fluprowit; Acetein; Airbron; Fabrol; Flumucetin; Mucosolvin; Fluimucetin; Mucosil; Brunac; Fluimicil Infantil; Acetylcysteinum; Acetilcisteina; Respaire; Mucofilin; Lysomucil; Exomuc; Inspir; Ac-Cys-OH; Mucolyticum Lappe; Mucolytikum Lappe; N-Acetyl cysteine; Mucolyticum; LNAC; N-Acetyl-3-mercaptoalanine; N-Acetyl-L-(+)-cysteine; Neo-fluimucil; NAC-TB; Mucolyticum-Lappe; (R; Acetylcysteine
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cystic fibrosis DIS2OK1Q CA25 Approved [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 074037.
2 ClinicalTrials.gov (NCT04279197) Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu. U.S. National Institutes of Health.